The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Latest updates on liso-cel for R/R CLL/SLL
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the latest research investigating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), including updates from the ongoing Phase I TRANSCEND-CLL-004 study (NCT03331198). This study has found that liso-cel monotherapy achieves a high rate of undetectable measurable residual disease (uMRD), with 75% of patients having uMRD in the blood. Liso-cel has also demonstrated a manageable safety profile and promising efficacy in combination with ibrutinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
